Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Consolidated Net Income: 2009-2024

Historic Consolidated Net Income for Madrigal Pharmaceuticals (MDGL) over the last 16 years, with Dec 2024 value amounting to -$465.9 million.

  • Madrigal Pharmaceuticals' Consolidated Net Income fell 3.88% to -$111.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$286.0 million, marking a year-over-year increase of 44.86%. This contributed to the annual value of -$465.9 million for FY2024, which is 24.69% down from last year.
  • Latest data reveals that Madrigal Pharmaceuticals reported Consolidated Net Income of -$465.9 million as of FY2024, which was down 24.69% from -$373.6 million recorded in FY2023.
  • In the past 5 years, Madrigal Pharmaceuticals' Consolidated Net Income ranged from a high of -$202.3 million in FY2020 and a low of -$465.9 million during FY2024.
  • Moreover, its 3-year median value for Consolidated Net Income was -$373.6 million (2023), whereas its average is -$378.3 million.
  • Data for Madrigal Pharmaceuticals' Consolidated Net Income shows a maximum YoY tumbled of 141.03% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Madrigal Pharmaceuticals' Consolidated Net Income stood at -$202.3 million in 2020, then fell by 19.66% to -$242.1 million in 2021, then declined by 21.99% to -$295.4 million in 2022, then decreased by 26.50% to -$373.6 million in 2023, then fell by 24.69% to -$465.9 million in 2024.